1.69
+2.42%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CANbridge Pharmaceuticals
Its shares trade on HKEX under the ticker 1228.HK. It has been listed since 10 December 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥50.0m and net income of CN¥14.8m. At that date it held total assets of CN¥165.5m and shareholders' equity of −CN¥341.9m.
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 10 Dec 2021
- Employees
- 118
- Website
- canbridgepharma.com ↗
Leadership
Pay as last reported
- Dr. Qun XueExecutive Chairman of the Board, Chief Executive Officer, Founder, since 2018CN¥13.1m
- Mr. Glenn HassanChief Financial Officer
- Ms. Qian MaJoint Company Secretary
- Mr. Wai Chiu WongJoint Company Secretary
- Dr. Kan ChenNon-Executive Director
- Mr. Edward HuNon-Executive Director
- Mr. Peng Kuan ChanIndependent Non-Executive DirectorCN¥202,000
- Mr. James GeraghtyIndependent Non-Executive DirectorCN¥202,000
- Dr. Richard GregoryIndependent Non-Executive DirectorCN¥202,000
- Dr. Lan HuNon-Executive Independent DirectorCN¥208,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CANbridge Pharmaceuticals Inc operates as a rare disease-focused biopharmaceutical company.
- The firm employs 118 full-time employees in Suzhou, Jiangsu.
- The main product is the glycosylated fusion protein CAN008 for treating glioblastoma.
Weaknesses
- The company went public on 2021-12-10 via an IPO.
- The firm is engaged in the development of gene therapy.
- The products are mainly used in rare diseases such as Hunter's syndrome.
Opportunities
- The company is committed to the research and development of transformative therapies.
- The firm handles the production, promotion, and sales of medical products.
- The business covers rare tumors and other fields beyond standard treatments.
Threats
- The ISIN KYG1821D1097 identifies the entity in financial markets.
- The ticker 1228.HK lists the company on the stock exchange.
- The website https://www.canbridgepharma.com/ serves as the primary online presence.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.